Erlotinib Hydrochloridis CAS 183319-69-9 Puritas >99.0% (HPLC)

Description:

Nomen chemicum: Erlotinib Hydrochloride

Synonyma: Erlotinib HCl;Tarceva

CAS: 183319-69-9

Puritas (HPLC): >99.0%

Aspectus: Alba ad Off-White Crystalline pulveris

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ducens fabrica et supplementum de Hydrochloride Erlotinib intermedia
Erlotinib Hydrochloridis CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxydorum) -3H-Quinazolin-4-unum CAS 179688-29-0
Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	Erlotinib Hydrochloride
Synonyma	Erlotinib HCl;Tarceva;CP-358774 Hydrochloride;6,7-Bis(2-methoxyethoxydum)-4-(3-ethynylanilinum)quinazolinum hydrochloridum;N-(3-Ethynylphe nyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine HCl
CAS Number	183319-69-9
CATTUS Number	RF-PI2242
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C22H24ClN3O4
M. Pondus	429.90
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White Crystalline pulveris
Lepidium sativum	A: IR: secundum Imaginem Reference B: HPLC: secundum quod referat RT
Solubilitas	Leviter solutum in aqua, modice solubile in Methanolo et insolubile in Acetonitrile, Acetone, Ethyl, Acetate et Hexane.
Liquescens punctum	223.0~229.0℃
Damnum in Siccatio	<0.50%
Residere in Ignition	<0.20%
Metalla gravis	<20ppm
una immunditia	<0.50%
Totalis immunditias	<1.00%
RELICTUM Solvents
Pyridine	<4000ppm
Chloroform	<4000ppm
DMF	<3000ppm
Puritas / Analysis Methodus	>99.0%
Asssay / Analysis Methodo	98.5%~ 101.0% (Caculated on Anhydrous Basis)
Test Standard	Enterprise Standard
Consuetudinem	API

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Hydrochloridis Erlotinib (CAS: 183319-69-9) est parva molecula incrementi epidermalis receptoris tyrosini kinasi convertibilis inhibitoris receptantis, in curatione locali provectae vel metastaticae non parvae cellae cancri et secundae lineae vel tres lineae curationis cancer pancreatis.Erlotinib Hydrochloride probata mense Novembri, 2004, ad curationem cancri pulmonis non-minutae metastaticae provectus est.Eiusdem generis est cum Gefitinib, alterum quinazolinum probatum ad curationem cancri pulmonis provectae, sed cum melioribus proprietatibus pharmacokineticis.Moleculum a Pfizer ortum est et progressum in cooperatione cum OSI initiatum est, quod pleno iure medicamento cum Pfizer cum Warner Lambert immiscuit.Postmodum, Genentech/Roche consensum licentiae iniit cum OSI ad explicandum et mercatum medicatum in Civitates Foederatarum et Mundi.Inhibitoris epidermalis incrementi selectivi factor (EGFR) -tyrosinus inhibitor kinasus.Antineoplastic.Hydrochloridis Erlotinib est HER1/EGFR inhibitor cum IC50 2 nm.Erlotinib HCl praesto est ut 25-, 100-, et 150-mg tabulae fororalis administratio.